Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Moderna, Inc. (MRNA) vs VanEck Rare Earth/Strategic Metals (REMX) Price & Performance

Moderna, Inc.Trade
VanEck Rare Earth/Strategic MetalsTrade

Price performance (Past 24H)

Key statistics

Moderna, Inc. vs VanEck Rare Earth/Strategic Metals — how do they compare? Moderna, Inc. trades at $60.51 (market cap $24.18B), while VanEck Rare Earth/Strategic Metals trades at $77.05. The key difference: Moderna, Inc. is trading nearer its 52-week high, VanEck Rare Earth/Strategic Metals nearer its low. Which is the better fit depends on your goals.

MRNAREMX
Market Cap
$24.18B
Sector
HealthSector/Thematic
52-Week High
$81.80$109.53
52-Week Low
$22.36$56.60
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Moderna, Inc.

Moderna (MRNA) trades at $63.70, up 6.5% recently, with a bullish technical signal and strong moving average support. Despite negative net income margins, the company beat Q2 2026 EPS estimates and secured FDA approval for its mRNA flu vaccine, mFLUSIVA, signaling diversification beyond COVID-19. Revenue has declined from pandemic peaks but is projected to stabilize around $2.2B in 2026.

The outlook is mixed: near-term catalysts from new vaccine approvals and pipeline progress offer upside, but persistent losses and high valuation multiples pose risks. Analyst consensus is cautious with a hold-heavy rating, reflecting uncertainty over profitability timelines amid ongoing R&D investments.

VanEck Rare Earth/Strategic Metals

REMX (VanEck Rare Earth and Strategic Metals ETF) trades at $77.24, down 1.54% with a bullish technical signal supported by moving averages. The ETF provides exposure to 38 global rare earth companies amid growing U.S. efforts to secure critical mineral supply chains. Recent news highlights Energy Fuels' Utah plant expansion and ongoing geopolitical focus on reducing China's rare earth dominance.

Outlook remains tied to U.S. industrial policy and rare earth demand, though high volatility (~50% annualized) and China concentration pose risks. Investor sentiment is mixed, balancing strategic importance against execution challenges in building domestic supply chains.

Returns comparison

Trailing returns across standard periods

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA

About VanEck Rare Earth/Strategic Metals

REMX invests in global companies involved in producing, refining, and recycling rare earth and strategic metals. It provides targeted exposure to critical minerals used in high-tech and green energy, with top holdings like Albemarle and Pilbara Minerals.

Read more on REMX